Antineutrophil cytoplasmic antibodies-associated vasculitis (AAV) is associated with high morbidity or mortality, especially if not promptly diagnosed and treated. Many inroads have been made in the understanding of the pathophysiology that leads to exploration of novel therapies. Randomized controlled trials over the last 2 decades have better delineated and expanded therapeutic options and set the stage for an evidence-based approach. Since 2014, 4 scientific societies have systematically reviewed the existing data and have formulated evidence-based recommendations for the management of AAV. These recommendations cover diagnosis, remission induction and maintenance treatment, and prevention of long-term complications. This review is a comparative analysis of the recently published recommendations of the European League Against Rheumatism/European Renal Association-European Dialysis and Transplant Association, the British Society of Rheumatology, the Canadian Vasculitis Research Network, and the Brazilian Society of Rheumatology, and aims to determine common ground among them and highlights the differences among the recommendations.

Department of Medicine Charles University Prague Prague Czech Republic

Department of Medicine Johns Hopkins University Baltimore Maryland USA

Department of Medicine Mount Sinai Hospital University Health Network Toronto Ontario Canada

Department of Medicine Trinity Health Kidney Center Tallaght Hospital Dublin Ireland

Department of Medicine University of Cambridge Cambridge UK

Zobrazit více v PubMed

Ntatsaki E., Carruthers D., Chakravarty K. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 2014;53:2306–2309. PubMed

Lapraik C., Watts R., Bacon P. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007;46:1615–1616. PubMed

McGeoch L., Twilt M., Famorca L. CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides. J Rheumatol. 2016;43:97–120. PubMed

Yates M., Watts R.A., Bajema I.M. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583–1594. PubMed

Mukhtyar C., Guillevin L., Cid M.C., European Vasculitis Study Group EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310–317. PubMed

Souza A.W.S., Calich A.L., Mariz H.A. Recommendations of the Brazilian Society of Rheumatology for the induction therapy of ANCA-associated vasculitis. Rev Bras Reumatol Engl Ed. 2017;57 Suppl 2:484–496. PubMed

Dougados M., Betteridge N., Burmester G.R. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis. 2004;63:1172–1176. PubMed PMC

Guyatt G.H., Oxman A.D., Kunz R., GRADE Working Group Going from evidence to recommendations. BMJ. 2008;336:1049–1051. PubMed PMC

Bossuyt X., Cohen Tervaert J., Arimura Y. Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017;13:683–692. PubMed

de Groot K., Harper L., Jayne D.R.W. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670–680. PubMed

de Groot K., Adu D., Savage C.O., EUVAS (European Vasculitis Study Group) The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant. 2001;16:2018–2027. PubMed

Stone J.H., Merkel P.A., Spiera R. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–232. PubMed PMC

Jones R.B., Cohen Tervaert J.W. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211–220. PubMed

Ribi C., Cohen P., Pagnoux C. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008;58:586–594. PubMed

Ribi C., Cohen P., Pagnoux C. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum. 2010;62:1186–1197. PubMed

Kimura M., Tanaka S., Ishikawa A. Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease. Rheumatol Int. 2008;28:673–676. PubMed

Ozen S., Pistorio A., Iusan S.M. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69:798–806. PubMed

Suppiah R., Mukhtyar C., Forssmann O. A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology. 2011;50:899–905. PubMed

Merkel P.A., Aydin S.Z., Boers M. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol. 2011;38:1480–1486. PubMed PMC